Probiotics function as anti-HIV agents: Probiotic Bacillus subtilis B10 increases Heme oxygenase 2 (HO-2) expression, blocks N-myristoylation of HIV-1 Gag protein, disrupts HIV-1 budding, and restricts HIV-1 production, via upregulation of its target gene, 28/February/2019, 8.09 am

Combinatorial therapy for Deafness: A therapeutic mix encompassing 4-Phenylbutyrate (4-PBA), Cholecalciferol, Ajoene and DIM (PCAD)  increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration,  improves hearing loss via upregulation of its target genes, 28/February/2019, 8.00 am
February 28, 2019
Combinatorial anti-cancer therapy blocking GPC2 pathway and immune receptors enhances the efficacy of Cancer immunotherapy in Neuroblastoma: A therapeutic mix encompassing   Metformin, Navitoclax/ABT-263, Dasatinib and 2-Deoxy-d-glucose (MNDDG)  inhibits the expression of GPC2, increases IFNγ signalling, increases antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, inhibits neuroblastoma proliferation, decreases tumor burden and increases survival via up-regulation of its target gene, 28/February/2019, 8.23 am
February 28, 2019
Show all

National Science day special

*********

We wish everyone a very happy national science day. On this special occasion, we are happy to announce that Bio-Med/Pharma/Therapeutic/Clinical ideas posted today (28/February/2019) will be available to the use of Scientists/Professors/Faculties/Teachers/Physicians/Researchers for free. So, there will be no terms and conditions for the ideas posted today. Each idea posted will be served first come, first serve basis. Write to admin@genomediscovery.org for more details.

Dr L Boominathan PhD

President, Director & CSO, GBMD.

_________________________________________________________________________________________________________________________________________________

 

 

What we say:

Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Probiotics function as anti-HIV agents: Probiotic Bacillus subtilis B10 increases Heme oxygenase 2 (HO-2) expression, blocks N-myristoylation of HIV-1 Gag protein, disrupts HIV-1 budding, and restricts HIV-1 production, via upregulation of its target gene

[easy_payment currency=”USD”]


From Significance of the study to Public health relevance:

Given that: (1) more than 37 million people worldwide are living with HIV/AIDS; (2) there is no effective vaccine available for HIV/AIDS; (3) HIV/AIDS tops the list of incurable diseases in humans; (4) the life-long painful drug treatment is required to treat HIV/AIDS and its associated opportunistic infections; (5) the global economic cost spent for HIV treatment is enormous, there is an urgent need to find: (i) a way to restore CD4 T-cells that were lost in HIV/AIDS; (ii) a cheaper alternative to the existing expensive antiviral drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, HIV-1/AIDS.


Research findings to Therapeutic opportunity:

A number of studies suggest that probiotics may protect against a number of bacterial infections. However, the mechanism of action remains unclear. I had published earlier that probiotics may function as anti-infective agents–presented with detailed mechanistic insights– against a number of bacterial and viral infections.

This study suggests a probiotic-based antiviral therapy against RNA viruses such as HIV-1. Probiotic Bacillus subtilis B10, by increasing the expression of its target gene, it may increase the expression of Heme oxygenase-2 (HO-2) (Figure 1). Thereby, it may: (1) bind and block the myristate moiety of HIV-1 Gag protein; (2) disrupt HIV-1 budding; (3) restrict HIV-1 infectivity, replication, and production; (4) promote clearance of HIV-1 and MLV virions; and (5) strengthen antiviral immunity against RNA viruses (fig.2). Thus, Probiotic Bacillus subtilis B10, either alone or in combination with other drugs,” may be used to inhibit HIV-1 production.

Figure 1 Mechanistic insights into how probiotic Bacillus subtilis B10 functions as an anti-HIV agent. Lactobacillus casei strain shirota (LcS) inhibits HIV-1 budding and production via up-regulation of its target gene HO-2

Figure 2. Probiotic Bacillus subtilis B10 functions as an anti-HIV agent.through induction of its target gene HO-2

[easy_payment currency=”USD”]

Together, this study suggests that: (1) Probiotic Bacillus subtilis B10 may function as an anti-retroviral agent against HIV infections, and (2) daily intake of Probiotic Bacillus subtilis B10 may protect against HIV1 infections.


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Probiotic Bacillus subtilis B10 increase the expression of Heme oxygenase-2 (HO-2)?

Amount: $500#

For payment and purchase details, you may reach us at admin@genomediscovery.org

# Research cooperation


References:

Web: http://genomediscovery.org or http://newbioideas.com/

Citation: Boominathan, L., Probiotics function as anti-HIV agents: Probiotic Bacillus subtilis B10 increases Heme oxygenase 2 (HO-2) expression, blocks N-myristoylation of HIV-1 Gag protein, disrupts HIV-1 budding, and restricts HIV-1 production, via upregulation of its target gene, 28/February/2019, 8.08 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at admin@genomediscovery.org

Comments are closed.